Base de dados : MEDLINE
Pesquisa : C04.557.470.035.415 [Categoria DeCS]
Referências encontradas : 561 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 57 ir para página                         

  1 / 561 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390316
[Au] Autor:Zhao Y; Zhang H; Lian W; Xing B; Feng M; Liu X; Wang R
[Ad] Endereço:Department of Neurosurgery, Peking Union Medical College Hospital.
[Ti] Título:Collision tumors composed of meningioma and growth hormone-secreting pituitary adenoma in the sellar region: Case reports and a literature review.
[So] Source:Medicine (Baltimore);96(50):e9139, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Collision tumor is a rare disease that represents the coexistence of two histologically distinct neoplasms in the same area without histological admixture or an intermediate cell population zone. To our best knowledge, 13 cases besides our 2 cases have been reported till now, and our report represents the first publication regarding a collision tumor composed of growth hormone (GH)-secreting pituitary adenoma and sellar meningioma. PATIENT CONCERNS: We collected two cases of collision tumors composed of meningioma and GH-secreting adenoma in the sellar region from 2014 to 2015 at Peking Union Medical College Hospital (PUMCH). DIAGNOSIS: Two cases were diagnosed with solid sellar tumors, and two tumor types were suspected with magnetic resonance imaging (MRI). Blood hormone tests revealed increased insulin-like growth factor 1 (IGF-1) and GH levels. INTERVENTIONS: Both cases underwent transsphenoidal microsurgical resection of pituitary adenoma. OUTCOMES: The tumor was completely resected, and the pathological examination after the operation revealed meningioma and GH-secreting pituitary adenoma. LESSONS: Collision tumors consisting of pituitary adenomas with other sellar neoplasms are rare. Histological examination is necessary because preoperative studies cannot guarantee an accurate diagnosis. If a collision tumor is suspected prior to operation, a craniotomy may need to be considered before other operation methods to avoid reoperation.
[Mh] Termos MeSH primário: Adenoma Hipofisário Secretor de Hormônio do Crescimento/patologia
Neoplasias Meníngeas/patologia
Meningioma/patologia
Neoplasias Primárias Múltiplas/patologia
Sela Túrcica/patologia
[Mh] Termos MeSH secundário: Feminino
Adenoma Hipofisário Secretor de Hormônio do Crescimento/diagnóstico por imagem
Adenoma Hipofisário Secretor de Hormônio do Crescimento/cirurgia
Seres Humanos
Imagem por Ressonância Magnética
Neoplasias Meníngeas/diagnóstico por imagem
Neoplasias Meníngeas/cirurgia
Meningioma/diagnóstico por imagem
Meningioma/cirurgia
Meia-Idade
Neoplasias Primárias Múltiplas/diagnóstico por imagem
Neoplasias Primárias Múltiplas/cirurgia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009139


  2 / 561 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29339530
[Au] Autor:Kasuki L; Wildemberg LE; Gadelha MR
[Ad] Endereço:Neuroendocrinology Research Center/Endocrine Section and Medical SchoolHospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
[Ti] Título:MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly.
[So] Source:Eur J Endocrinol;178(3):R89-R100, 2018 Mar.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Acromegaly is associated with high morbidity and elevated mortality when not adequately treated. Surgery is the first-line treatment for most patients as it is the only one that can lead to immediate cure. In patients who are not cured by surgery, treatment is currently based on a trial-and-error approach. First-generation somatostatin receptor ligands (fg-SRL) are initiated for most patients, although approximately 25% of patients present resistance to this drug class. Some biomarkers of treatment outcome are described in the literature, with the aim of categorizing patients into different groups to individualize their treatments using a personalized approach. In this review, we will discuss the current status of precision medicine for the treatment of acromegaly and future perspectives on the use of personalized medicine for this purpose.
[Mh] Termos MeSH primário: Acromegalia/tratamento farmacológico
Adenoma/tratamento farmacológico
Agonistas de Dopamina/uso terapêutico
Adenoma Hipofisário Secretor de Hormônio do Crescimento/tratamento farmacológico
Medicina de Precisão
Receptores da Somatotropina/antagonistas & inibidores
Somatostatina/análogos & derivados
[Mh] Termos MeSH secundário: Seres Humanos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Dopamine Agonists); 0 (Receptors, Somatotropin); 51110-01-1 (Somatostatin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-1006


  3 / 561 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29328563
[Au] Autor:Dragovic T; Duran Z; Jelic S; Marinkovic D; Kikovic S; Kuzmic-Jankovic S; Hajdukovic Z
[Ti] Título:Coexisting diseases modifying each other's presentation - lack of growth failure in Turner syndrome due to the associated pituitary gigantism.
[So] Source:Vojnosanit Pregl;73(10):961-6, 2016 Oct.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Introduction: Turner syndrome presents with one of the most frequent chromosomal aberrations in female, typically presented with growth retardation, ovarian insufficiency, facial dysmorphism, and numerous other somatic stigmata. Gigantism is an extremely rare condition resulting from an excessive growth hormone (GH) secretion that occurs during childhood before the fusion of epiphyseal growth plates. The major clinical feature of gigantism is growth acceleration, although these patients also suffer from hypogonadism and soft tissue hypertrophy. Case report: We presented a girl with mosaic Turner syndrome, delayed puberty and normal linear growth for the sex and age, due to the simultaneous GH hypersecretion by pituitary tumor. In the presented case all the typical phenotypic stigmata related to Turner syndrome were missing. Due to excessive pituitary GH secretion during the period while the epiphyseal growth plates of the long bones are still open, characteristic stagnation in longitudinal growth has not been demonstrated. The patient presented with delayed puberty and primary amenorrhea along with a sudden appearance of clinical signs of hypersomatotropinism, which were the reasons for seeking medical help at the age of 16. Conclusion: Physical examination of children presenting with delayed puberty but without growth arrest must include an overall hormonal and genetic testing even in the cases when typical clinical presentations of genetic disorder are absent. To the best of our knowledge, this is the first reported case of simultaneous presence of Turner syndrome and gigantism in the literature.
[Mh] Termos MeSH primário: Adenoma/complicações
Desenvolvimento do Adolescente
Estatura
Gigantismo/etiologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/complicações
Síndrome de Turner/complicações
[Mh] Termos MeSH secundário: Adenoma/sangue
Adenoma/fisiopatologia
Adenoma/cirurgia
Adolescente
Amenorreia/etiologia
Amenorreia/fisiopatologia
Biomarcadores/sangue
Feminino
Gigantismo/sangue
Gigantismo/fisiopatologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/sangue
Adenoma Hipofisário Secretor de Hormônio do Crescimento/fisiopatologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/cirurgia
Terapia de Reposição Hormonal
Hormônio do Crescimento Humano/sangue
Seres Humanos
Fator de Crescimento Insulin-Like I/metabolismo
Imagem por Ressonância Magnética
Mosaicismo
Puberdade Tardia/etiologia
Puberdade Tardia/fisiopatologia
Resultado do Tratamento
Síndrome de Turner/tratamento farmacológico
Síndrome de Turner/genética
Síndrome de Turner/fisiopatologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (IGF1 protein, human); 12629-01-5 (Human Growth Hormone); 67763-96-6 (Insulin-Like Growth Factor I)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150620014D


  4 / 561 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28732322
[Au] Autor:Fortunati N; Guaraldi F; Zunino V; Penner F; D'Angelo V; Zenga F; Pecori Giraldi F; Catalano MG; Arvat E
[Ad] Endereço:Division of Oncological Endocrinology, Città della Salute e della Scienza University Hospital, I-10126 Turin, Italy.
[Ti] Título:Effects of environmental pollutants on signaling pathways in rat pituitary GH3 adenoma cells.
[So] Source:Environ Res;158:660-668, 2017 10.
[Is] ISSN:1096-0953
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:An increased rate of acromegaly was reported in industrialized areas, suggesting an involvement of environmental pollutants in the pathogenesis and behavior of GH-secreting pituitary adenomas. Based on these premises, the aim of the study was to evaluate the effects of some widely diffused pollutants (i.e. benzene, BZ; bis(2-ethylhexyl) phthalate, DEHP and polychlorinated biphenyls, PCB) on growth hormone secretion, the somatostatin and estrogenic pathways, viability and proliferation of rat GH-producing pituitary adenoma (GH3) cells. All the pollutants induced a statistically significant increase in GH secretion and interfered with cell signaling. They all modulated the expression of SSTR2 and ZAC1, involved in the somatostatin signaling, and the expression of the transcription factor FOXA1, involved in the estrogen receptor signaling. Moreover, all the pollutants increased the expression of the CYP1A1, suggesting AHR pathway activation. None of the pollutants impacted on cell proliferation or viability. Present data demonstrate that exposure to different pollutants, used at in vivo relevant concentrations, plays an important role in the behavior of GH3 pituitary adenoma cells, by increasing GH secretion and modulating several cellular signaling pathways. These observations support a possible influence of different pollutants in vivo on the GH-adenoma aggressiveness and biological behavior.
[Mh] Termos MeSH primário: Poluentes Ambientais/toxicidade
Expressão Gênica/efeitos dos fármacos
Hormônio do Crescimento/metabolismo
Transdução de Sinais/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Benzeno/toxicidade
Linhagem Celular Tumoral
Sobrevivência Celular/efeitos dos fármacos
Dietilexilftalato/toxicidade
Estrogênios/genética
Estrogênios/metabolismo
Adenoma Hipofisário Secretor de Hormônio do Crescimento/induzido quimicamente
Bifenilos Policlorados/toxicidade
Ratos
Somatostatina/genética
Somatostatina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Environmental Pollutants); 0 (Estrogens); 51110-01-1 (Somatostatin); 9002-72-6 (Growth Hormone); C42K0PH13C (Diethylhexyl Phthalate); DFC2HB4I0K (Polychlorinated Biphenyls); J64922108F (Benzene)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171120
[Lr] Data última revisão:
171120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE


  5 / 561 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28705113
[Au] Autor:Wang J; Liu Q; Gao H; Wan D; Li C; Li Z; Zhang Y
[Ad] Endereço:1 Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
[Ti] Título:EGFL7 participates in regulating biological behavior of growth hormone-secreting pituitary adenomas via Notch2/DLL3 signaling pathway.
[So] Source:Tumour Biol;39(7):1010428317706203, 2017 Jul.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Growth hormone-secreting pituitary adenoma accounts for about 20% of the third most common intracranial neoplasm-pituitary adenomas-which makes up 15% of all intracranial tumors. The growth hormone-secreting pituitary adenoma invasion is a key risk factor associated with the operation results and highly correlated with the clinical prognosis. The epidermal growth factor-like domain multiple 7 protein, a unique 29 kDa secreted angiogenic factor, can result in pathologic angiogenesis and enhance the tumor migration and invasion. In this study, for the first time we found that epidermal growth factor-like domain multiple 7 protein expression was markedly higher in invasive growth hormone-secreting pituitary adenoma than non-invasive growth hormone-secreting pituitary adenoma. The tumor volume, histologic subtypes, invasiveness and recurrence of growth hormone-secreting pituitary adenoma were significantly associated with epidermal growth factor-like domain multiple 7 protein expression. Furthermore, we discovered that the histological classification methods of growth hormone-secreting pituitary adenoma according to electron microscopic examination and biological marker classification methods according to epidermal growth factor-like domain multiple 7 protein expression are more valuable in clinical application than the traditional classification methods based on Knosp and Hardy-Wilson grades. In summary, our results indicated epidermal growth factor-like domain multiple 7 protein participates in growth hormone-secreting pituitary adenoma proliferation and invasion regulation via Notch2/DLL3 signaling pathway. These findings raised the possibility that epidermal growth factor-like domain multiple 7 protein might serve as a useful biomarker to assess growth hormone-secreting pituitary adenoma invasion and prognosis or a potential therapeutic target for growth hormone-secreting pituitary adenoma treatment.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/genética
Neoplasias Encefálicas/genética
Fatores de Crescimento Endotelial/genética
Adenoma Hipofisário Secretor de Hormônio do Crescimento/genética
Peptídeos e Proteínas de Sinalização Intracelular/genética
Proteínas de Membrana/genética
Receptor Notch2/genética
[Mh] Termos MeSH secundário: Adulto
Neoplasias Encefálicas/patologia
Fatores de Crescimento Endotelial/biossíntese
Feminino
Regulação Neoplásica da Expressão Gênica
Adenoma Hipofisário Secretor de Hormônio do Crescimento/patologia
Seres Humanos
Masculino
Meia-Idade
Invasividade Neoplásica/genética
Invasividade Neoplásica/patologia
Recidiva Local de Neoplasia/genética
Recidiva Local de Neoplasia/patologia
Prognóstico
Transdução de Sinais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (DLL3 protein, human); 0 (EGFL7 protein, human); 0 (Endothelial Growth Factors); 0 (Intracellular Signaling Peptides and Proteins); 0 (Membrane Proteins); 0 (NOTCH2 protein, human); 0 (Receptor, Notch2)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170728
[Lr] Data última revisão:
170728
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170715
[St] Status:MEDLINE
[do] DOI:10.1177/1010428317706203


  6 / 561 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Lazarini, Paulo Roberto
Texto completo SciELO Brasil
[PMID]:28591390
[Au] Autor:Leopoldo CMDS; Leopoldo FMDS; Santos ARLD; Veiga JCE; Lima JV; Scalissi NM; Lazarini PR; Dolci RLL
[Ad] Endereço:Faculdade de Ciências Médicas, Santa Casa de São Paulo, São Paulo SP, Brasil.
[Ti] Título:Long term follow-up of growth hormone-secreting pituitary adenomas submitted to endoscopic endonasal surgery.
[So] Source:Arq Neuropsiquiatr;75(5):301-306, 2017 May.
[Is] ISSN:1678-4227
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Objective: The aim of this study was to evaluate the results of the endoscopic transsphenoidal technique for growth hormone (GH)-secreting adenomas. Methods: A retrospective analysis based on medical records of 23 acromegalic patients submitted to endoscopic transsphenoidal surgery. Biochemical control was defined as basal GH < 1ng/ml, nadir GH < 0.4ng/ml after glucose load and age-adjusted IGF-1 normal at the last follow-up. Results: The overall endocrinological remission rate was 39.1%. While all microademonas achieved a cure, just one third of macroadenomas went into remission. Suprasellar extension, cavernous sinus invasion and high GH levels were associated with lower rates of disease control. The most common complication was diabetes insipidus and the most severe was an ischemic stroke. Conclusion: The endoscopic transsphenoidal approach is a safe and effective technique to control GH-secreting adenomas. The transcavernous approach may increase the risk of complications. Suprasellar and cavernous sinus extensions may preclude gross total resection of these tumors.
[Mh] Termos MeSH primário: Acromegalia/cirurgia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/cirurgia
Neuroendoscopia/métodos
Neoplasias Hipofisárias/cirurgia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Neuroendoscopia/efeitos adversos
Estudos Retrospectivos
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170630
[Lr] Data última revisão:
170630
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170608
[St] Status:MEDLINE


  7 / 561 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28505364
[Au] Autor:Mavromati M; Kuhn E; Agostini H; Brailly-Tabard S; Massart C; Piketty ML; Arnoux A; Young J; Souberbielle JC; Chanson P
[Ad] Endereço:Service d'Endocrinologie et des Maladies de la Reproduction and Centre de Référence des Maladies Rares de l'Hypophyse, F94275 Le Kremlin-Bicêtre, France.
[Ti] Título:Classification of Patients With GH Disorders May Vary According to the IGF-I Assay.
[So] Source:J Clin Endocrinol Metab;102(8):2844-2852, 2017 Aug 01.
[Is] ISSN:1945-7197
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Context: Insulinlike growth factor I (IGF-I) measurement is essential for the diagnosis and management of growth hormone (GH) disorders. However, patient classification may vary substantially according to the assay technique. Objective: We compared individual patient data and classifications obtained with six different IGF-I assay kits in a group of patients with various GH disorders. Design: In this cross-sectional study, we measured IGF-I with six immunoassays in 102 patients with active or treated acromegaly or GH deficiency. IGF-I normative data previously established for the same six assay kits were used to classify the patients (high, low, or normal IGF-I levels), using both raw data and standard deviation scores (SDSs). Pairwise concordance between assays was assessed with Bland-Altman plots and with the percentage of observed agreement and the weighted κ coefficient for categorized IGF-I SDS. Results: We observed marked variability both across each individual's IGF-I raw data and across IGF-I SDS values obtained with each of the six immunoassays. Pairwise concordance between assay values, as assessed with the weighted κ coefficient, ranged from 0.50 (moderate) to 0.81 (excellent). Conclusion: Even when using normative data obtained in the same large population of healthy subjects and when using calculated IGF-I SDSs, agreement among IGF-I assay methods is only moderate to good. Differences in assay performance must be taken into account when evaluating and monitoring patients with GH disorders. This argues for the use of the same IGF-I assay for a given patient throughout follow-up.
[Mh] Termos MeSH primário: Acromegalia/metabolismo
Adenoma/metabolismo
Nanismo Hipofisário/metabolismo
Adenoma Hipofisário Secretor de Hormônio do Crescimento/metabolismo
Imunoensaio/métodos
Fator de Crescimento Insulin-Like I/metabolismo
[Mh] Termos MeSH secundário: Acromegalia/terapia
Adenoma/terapia
Adulto
Idoso
Estudos Transversais
Agonistas de Dopamina/uso terapêutico
Quimioterapia Combinada
Ergolinas/uso terapêutico
Feminino
Adenoma Hipofisário Secretor de Hormônio do Crescimento/terapia
Hormônio do Crescimento Humano/análogos & derivados
Hormônio do Crescimento Humano/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Procedimentos Neurocirúrgicos
Somatostatina/análogos & derivados
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dopamine Agonists); 0 (Ergolines); 12629-01-5 (Human Growth Hormone); 51110-01-1 (Somatostatin); 67763-96-6 (Insulin-Like Growth Factor I); LL60K9J05T (cabergoline); N824AOU5XV (pegvisomant)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170516
[St] Status:MEDLINE
[do] DOI:10.1210/jc.2017-00202


  8 / 561 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28492721
[Au] Autor:de Fátima Borges M; Lara BHJ; Tomé JM; de Araújo LP; Bugiga FCL; Sousa JC; Soares JMF; Dezena RA; Ferreira BP
[Ad] Endereço:Divisão de Endocrinologia e Metabolismo, Universidade Federal do Triângulo Mineiro, Uberaba, MG, BR.
[Ti] Título:Treatment of acromegaly patients at the Federal University of Triângulo Mineiro (UFTM): Experience Report.
[So] Source:Clinics (Sao Paulo);72(4):218-223, 2017 Apr.
[Is] ISSN:1980-5322
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE:: To evaluate the effectiveness of the treatment of acromegaly patients at the Federal University of Triangulo Mineiro. METHODS:: Cross-sectional and retrospective study of thirty cases treated over a period of two decades. RESULTS:: 17 men (56.7%) aged 14-67 years and 13 women aged 14-86 years were analyzed. Twenty-one patients underwent transphenoidal surgery, whichwas associated with somatostatin receptor ligands in 11 patients (39.3%), somatostatin receptor ligands + radiotherapyin 5 patients (17.8%), radiotherapy in 3 patients (10.7%), and radiotherapy + somatostatin receptorligands + cabergoline in 1 patient (3.6%). Additionally, 2 patients underwent radiotherapy and surgeryalone. Six patients received somatostatin receptor ligands before surgery, and 2 were not treated due to refusal and death. Nine patients have died, and 20 are being followed; 13 (65%) have growth hormonelevels o1 ng/mL, and 11 have normal insulin-like growth factor 1 levels. CONCLUSION:: The current treatment options enable patients seen in regional reference centers to achieve strict control parameters, which allows them to be treated close to their homes.
[Mh] Termos MeSH primário: Acromegalia/terapia
Adenoma/cirurgia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/cirurgia
Receptores de Somatostatina/metabolismo
[Mh] Termos MeSH secundário: Acromegalia/sangue
Adenoma/metabolismo
Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Glicemia/análise
Brasil
Terapia Combinada
Estudos Transversais
Feminino
Gigantismo/sangue
Gigantismo/terapia
Hormônio do Crescimento/sangue
Seres Humanos
Fator de Crescimento Insulin-Like I/análise
Ligantes
Masculino
Meia-Idade
Estudos Retrospectivos
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Ligands); 0 (Receptors, Somatostatin); 67763-96-6 (Insulin-Like Growth Factor I); 9002-72-6 (Growth Hormone)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170830
[Lr] Data última revisão:
170830
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170512
[St] Status:MEDLINE


  9 / 561 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28427982
[Au] Autor:Tosaka M; Higuchi T; Horiguchi K; Osawa T; Arisaka Y; Fujita H; Tsushima Y; Yoshimoto Y
[Ad] Endereço:Department of Neurosurgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. Electronic address: nstosaka@gunma-u.ac.jp.
[Ti] Título:Preoperative Evaluation of Sellar and Parasellar Macrolesions by [ F]Fluorodeoxyglucose Positron Emission Tomography.
[So] Source:World Neurosurg;103:591-599, 2017 Jul.
[Is] ISSN:1878-8769
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Various diseases can occur in the sellar and suprasellar regions. The potential of [ F]fluorodeoxyglucose (FDG) positron emission tomography (PET) for the preoperative evaluation of sellar and parasellar lesions was investigated. METHODS: A total of 49 patients aged 8-82 years with sellar and parasellar macroscopic lesions (≥10 mm) underwent FDG PET. Twenty-two patients had pituitary adenomas, including 14 nonfunctioning and 8 growth hormone-secreting adenomas. Eleven patients had craniopharyngiomas, including 5 adamantinomatous and 6 squamous-papillary types. Eight patients had chordoma, 4 had meningioma, and 4 had a Rathke cleft cyst. The maximum standardized uptake value (SUV ), and the ratio of the SUV in the tumor to the mean standardized uptake value in the normal cortex (T/N ratio) or in the normal white matter (T/W ratio) were calculated. The relationships between SUV , T/N ratio, and T/W ratio, and lesion disease were evaluated. RESULTS: Uptakes of FDG, including SUV , T/N ratio, and T/W ratio, were lower in chordoma and Rathke cleft cyst compared with pituitary adenoma. SUV , T/N ratio, and T/W ratio of nonfunctioning adenoma were significantly higher than those of growth hormone-secreting adenoma. SUV , T/N ratio, and T/W ratio of squamous-papillary type were significantly higher than those of the adamantinomatous type of craniopharyngioma. CONCLUSIONS: FDG PET is useful for the preoperative diagnosis of sellar and parasellar macrolesions. High uptake in nonfunctioning pituitary adenoma, and low uptake in chordoma are significant. The difference in FDG uptake dependent on the histologic subtype may be related to the specific genetics of the craniopharyngioma subtype.
[Mh] Termos MeSH primário: Adenoma/diagnóstico por imagem
Cistos do Sistema Nervoso Central/diagnóstico por imagem
Cordoma/diagnóstico por imagem
Craniofaringioma/diagnóstico por imagem
Adenoma Hipofisário Secretor de Hormônio do Crescimento/diagnóstico por imagem
Neoplasias Meníngeas/diagnóstico por imagem
Meningioma/diagnóstico por imagem
Neoplasias Hipofisárias/diagnóstico por imagem
Sela Túrcica/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adenoma/patologia
Adenoma/cirurgia
Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Cistos do Sistema Nervoso Central/patologia
Cistos do Sistema Nervoso Central/cirurgia
Criança
Cordoma/patologia
Cordoma/cirurgia
Craniofaringioma/patologia
Craniofaringioma/cirurgia
Feminino
Fluordesoxiglucose F18
Adenoma Hipofisário Secretor de Hormônio do Crescimento/patologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/cirurgia
Seres Humanos
Masculino
Neoplasias Meníngeas/patologia
Neoplasias Meníngeas/cirurgia
Meningioma/patologia
Meningioma/cirurgia
Meia-Idade
Neoplasias Hipofisárias/patologia
Neoplasias Hipofisárias/cirurgia
Tomografia por Emissão de Pósitrons
Cuidados Pré-Operatórios
Compostos Radiofarmacêuticos
Estudos Retrospectivos
Sela Túrcica/patologia
Sela Túrcica/cirurgia
Carga Tumoral
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Radiopharmaceuticals); 0Z5B2CJX4D (Fluorodeoxyglucose F18)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170422
[St] Status:MEDLINE


  10 / 561 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28323966
[Au] Autor:Fadini GP; Dassie F; Cappellari R; Persano M; Vigili de Kreutzenberg S; Martini C; Parolin M; Avogaro A; Vettor R; Maffei P
[Ad] Endereço:Department of Medicine, University of Padua, Padua 35128, Italy.
[Ti] Título:Persistent Reduction of Circulating Myeloid Calcifying Cells in Acromegaly: Relevance to the Bone-Vascular Axis.
[So] Source:J Clin Endocrinol Metab;102(6):2044-2050, 2017 Jun 01.
[Is] ISSN:1945-7197
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Context: Acromegaly is a systemic disease characterized by persistent bone pathology and excess cardiovascular mortality. Despite multiple concomitant risk factors, atherosclerosis does not seem to be accelerated in acromegaly. Objective: To compare the levels of circulating myeloid calcifying cells (MCCs), which promote ectopic calcification and inhibit angiogenesis, in individuals with and without acromegaly. Design: Cross-sectional case-control study. Setting: Tertiary ambulatory referral endocrinology center. Patients: 44 acromegalic patients (25 active; 19 inactive), 44 control subjects matched by age, sex, risk factors, and medications, and 8 patients cured of acromegaly. Intervention: MCCs were measured using flow cytometry based on the expression of osteocalcin (OC) and bone alkaline phosphatase (BAP) on monocytes and circulating CD34+ stem cells. Main Outcome Measure: Differences in MCCs between patients and controls. Results: OC+BAP+ MCCs were severely reduced in acromegalic compared with control patients (0.17% ± 0.02% vs 1.00% ± 0.24%; P < 0.001), as were the total OC+ and BAP+ monocytic cells. Patients with inactive acromegaly and those cured of acromegaly displayed persistently reduced levels of MCCs. In the controls, but not acromegalic patients, MCCs were increased in the presence of diabetes or cardiovascular disease. A direct correlation was noted between MCCs and parathyroid hormone (r = 0.61; P < 0.0001), supporting a link between bone biology and MCCs. Conclusions: In patients with acromegaly, the levels of MCCs are reduced and remain low, even years after a complete cure. This finding might be related to low atherosclerotic calcification and the persistence of bone pathology after acromegaly remission or cure.
[Mh] Termos MeSH primário: Adenoma/sangue
Adenoma Hipofisário Secretor de Hormônio do Crescimento/sangue
Monócitos/citologia
Células Mieloides/citologia
Células-Tronco/citologia
[Mh] Termos MeSH secundário: Adenoma/tratamento farmacológico
Fosfatase Alcalina/metabolismo
Antígenos CD34/metabolismo
Antineoplásicos Hormonais/uso terapêutico
Calcinose
Estudos de Casos e Controles
Estudos Transversais
Feminino
Citometria de Fluxo
Adenoma Hipofisário Secretor de Hormônio do Crescimento/tratamento farmacológico
Hormônio do Crescimento Humano/análogos & derivados
Hormônio do Crescimento Humano/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Monócitos/metabolismo
Células Mieloides/metabolismo
Neovascularização Fisiológica
Osteocalcina/metabolismo
Somatostatina/análogos & derivados
Células-Tronco/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD34); 0 (Antineoplastic Agents, Hormonal); 104982-03-8 (Osteocalcin); 12629-01-5 (Human Growth Hormone); 51110-01-1 (Somatostatin); EC 3.1.3.1 (ALPL protein, human); EC 3.1.3.1 (Alkaline Phosphatase); N824AOU5XV (pegvisomant)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170322
[St] Status:MEDLINE
[do] DOI:10.1210/jc.2017-00246



página 1 de 57 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde